MedTrace Logo

Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma

NCT02919332 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-07-24

No results posted yet for this study

Summary

This clinical trial studies how well delayed fludeoxyglucose F-18 (18F-FDG) positron emission tomography (PET)/computed tomography (CT) works in improving visualization of brain tumors in patients with glioblastoma. Radiotracers such as 18F-FDG are highly taken up by tumors in the brain and are visualized using PET/CT. Increasing the interval of time between 18F-FDG administration and PET/CT scan may improve the visualization of brain tumors in patients with glioblastoma.

Conditions

Interventions

PROCEDURE

Computed Tomography

Undergo 18F-FDG PET/CT

RADIATION

Fludeoxyglucose F-18

Given IV

PROCEDURE

Positron Emission Tomography

Undergo 18F-FDG PET/CT

Sponsors & Collaborators

  • Jonsson Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Johannes Czernin · UCLA / Jonsson Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-08
Primary Completion
2018-12-12
Completion
2018-12-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02919332 on ClinicalTrials.gov